Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by TD Cowen

TD Cowen cut shares of Keros Therapeutics (NASDAQ:KROS - Free Report) from a buy rating to a hold rating in a research report report published on Thursday morning, MarketBeat.com reports.

A number of other brokerages also recently commented on KROS. Guggenheim reissued a "buy" rating and issued a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. William Blair lowered Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wells Fargo & Company raised their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $95.22.

Keros Therapeutics Trading Down 73.2 %

NASDAQ:KROS traded down $50.22 on Thursday, hitting $18.43. 14,631,993 shares of the stock were exchanged, compared to its average volume of 437,409. The stock has a fifty day moving average of $60.78 and a 200-day moving average of $53.07. The stock has a market cap of $746.54 million, a PE ratio of -3.08 and a beta of 1.20. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same period in the previous year, the business posted ($1.33) earnings per share. The business's quarterly revenue was up 4750.0% on a year-over-year basis. As a group, analysts predict that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the second quarter valued at $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics during the third quarter worth $213,000. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.